Schilsky Richard L
American Society of Clinical Oncology, Alexandria, VA, 22314 USA.
Ecancermedicalscience. 2013 Aug 29;7:344. doi: 10.3332/ecancer.2013.344. eCollection 2013.
The Worldwide Innovative Networking (WIN) consortium is a global alliance of academic and industrial cancer researchers, clinicians, and cancer advocacy groups set up to promote innovations in personalised cancer therapy and to accelerate the translation of research in this discipline into the oncology clinic. One of its most important initiatives is the WIN symposia, which have been held in Paris each summer since 2009. The fifth WIN symposium, which was held 10-12 July 2013, took as its overall theme 'Personalised Cancer Therapy: From Innovation to Implementation'. Over 400 delegates, including a good number of representatives of patient groups as well as leading academic, industrial, and clinical scientists; students; and post-docs attended this symposium. Its scientific programme featured thirty presentations divided into four main plenary sessions, and there was also a wide-ranging poster session that encompassed all the topics covered in the plenaries. The programme structure followed the path of drug discovery, in that the first session covered assay development for personalised cancer medicine; the second, applications of genomics in oncology; the third, clinical development; and the fourth, the impact of personalised medicine on cancer care.
全球创新网络（WIN）联盟是一个由学术和产业界癌症研究人员、临床医生以及癌症倡导组织组成的全球联盟，其设立目的是促进个性化癌症治疗方面的创新，并加速该领域研究成果转化至肿瘤临床实践中。其最重要的举措之一是WIN研讨会，自2009年起每年夏天在巴黎举办。2013年7月10日至12日举行的第五届WIN研讨会的总体主题为“个性化癌症治疗：从创新到实施”。400多名代表参加了此次研讨会，其中包括众多患者团体代表以及顶尖学术、产业和临床科学家、学生和博士后。其科学议程包括30场演讲，分为四个主要全会，还有一个涵盖全会所有主题的广泛海报展示环节。议程结构遵循药物研发路径，即第一场会议涵盖个性化癌症药物的检测方法开发；第二场会议是基因组学在肿瘤学中的应用；第三场会议是临床开发；第四场会议是个性化医疗对癌症护理的影响。
